Werewolf Therapeutics, Inc. (HOWL) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Werewolf Therapeutics, Inc. (HOWL) Earnings Overview
As of June 23, 2026, Werewolf Therapeutics, Inc. (HOWL) reported trailing twelve-month net income of -$56M, reflecting +18.4% year-over-year growth. The company earned $-1.14 per diluted share over the past four quarters.
Looking at the long-term picture, HOWL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2019.
Werewolf Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTX (-$100M net income), IMVT (-$506M net income), AGEN ($65M net income, 0.1% margin), HOWL has comparable earnings metrics. Compare HOWL vs NKTX →
HOWL Earnings vs Peers
Earnings metrics vs comparable public companies
HOWL Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$61M | +13.7% | -$61M | $-1.33 | - | - |
| 2024 | -$71M | -88.7% | -$74M | $-1.63 | -3740.8% | -3904.2% |
| 2023 | -$37M | +30.6% | -$41M | $-1.05 | -187.4% | -203.1% |
| 2022 | -$54M | -7.7% | -$56M | $-1.86 | -328.1% | -341.8% |
| 2021 | -$50M | -234.6% | -$50M | $-10.94 | - | - |
| 2020 | -$15M | -35.9% | -$22M | $-0.98 | - | - |
| 2019 | -$11M | - | -$10M | $-0.38 | - | - |
Download Data
Export HOWL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HOWL — Frequently Asked Questions
Quick answers to the most common questions about buying HOWL stock.
What is HOWL earnings per share (EPS)?
HOWL trailing twelve-month (TTM) diluted EPS is $-1.14, reflecting +18.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Werewolf Therapeutics, Inc.'s net income?
Werewolf Therapeutics, Inc. (HOWL) trailing twelve-month net income is $-56M as of 2025. Earnings grew +18.4% year-over-year.
Is HOWL profitable?
HOWL is not currently profitable on a TTM basis, reporting a net loss of $-56M. Net margin is N/A. Investors should monitor for a return to profitability.
What is HOWL's earnings growth rate?
HOWL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are HOWL's profit margins?
Werewolf Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -123.9%.
Is HOWL growing earnings?
Yes, HOWL earnings are accelerating — EPS growth of +18.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-56M. Earnings momentum is strengthening.
What was HOWL's best earnings year?
Werewolf Therapeutics, Inc.'s highest annual net income on record is $-11M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were HOWL's earnings last quarter?
HOWL's most recent reported quarter was Q1 2026. Net income was $-14M with diluted EPS of $-0.28. For a full breakdown of all quarters, see the quarterly earnings table on this page.